Vzarii Therapeutics

Executive Summary

Vzarii Therapeutics is a preclinical-stage biotechnology company pioneering gene therapy solutions for neurodegenerative diseases by targeting mitochondrial dysfunction. Founded in 2021 and based in Dublin, Ireland, the company leverages proprietary research from Trinity College Dublin to develop innovative therapies for prevalent conditions such as Parkinson's and Alzheimer's diseases. Mitochondrial dysfunction is a key driver of neuronal cell death in these disorders, and Vzarii's gene therapy approach aims to restore mitochondrial health and function, offering a disease-modifying strategy. The company is currently in the discovery and preclinical development phase, focusing on lead optimization and initial in vivo proof-of-concept studies. With a strong scientific foundation and a clear unmet medical need, Vzarii Therapeutics is positioned to address the significant challenges in neurodegenerative disease treatment.

Upcoming Catalysts (preview)

• Q3 2026Lead candidate selection and in vivo proof-of-concept data50% success
• Q1 2027IND-enabling studies initiation40% success
• Q4 2026Partnership or licensing deal for preclinical pipeline30% success